New England Research Associates LLC | Bridgeport, CT
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Have, within the last 4 years, been diagnosed with T2D based on the World Health Organization classification or other locally applicable diagnostic standards.
Have HbA1c ≥7% to ≤9.5% as determined by the central laboratory.
Have been on a stable treatment of metformin only at least 90 days preceding baseline
Exclusion criteria
Have type 1 diabetes mellitus
Have a history of chronic or acute pancreatitis any time prior to study entry
Have a history of
Are at high risk for cardiovascular disease (CVD) in the investigator's opinion or have a history of any of these CV conditions prior to study entry
Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)
Have within 90 days prior to screening received treatment with medications intended to promote weight loss. This includes prescribed, over the counter, or alternative remedies
Have an estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73 m2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label), calculated by chronic kidney disease-epidemiology equation as determined by central laboratory at screening.
Have been treated with any injectable glucagon-like peptide-1 (GLP-1) receptor agonists and insulin prior to screening.
Primary purpose
Allocation
Interventional model
Masking
780 participants in 2 patient groups
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CT LILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal